Key facts
- CGenetix’s last known valuation is $4.5M (Nov 2025).
- It has raised $610K; the latest was Seed Round ($250K) in Nov 2025.
- Notable investors include BSV Ventures, Calyseed, Genopole, Paris Biotech Sante.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for CGenetix
- ·The full record, as it builds
Funding rounds
No funding rounds for CGenetix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CGenetix
Operator of a molecular diagnostic company intended to offer non-invasive monitoring of transplant patients' organ health. The company offers liquid biopsy-based testing, epigenetic analysis, and digital polymerase chain reaction technologies, enabling healthcare providers to detect organ damage early, and improving patient care and quality of life.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 6
- Website
- cgenetix.com/
- Ownership
- Privately Held (backing)
CGenetix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CGenetix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CGenetix in its N-PORT filings yet. We sweep new filings monthly.